Cantabio
is a California-based biotechnology company that researches and develops novel therapeutics to treat neurodegenerative and metabolic diseases... Read moreCantabio
is a California-based biotechnology company that researches and develops novel therapeutics to treat neurodegenerative and metabolic diseases... Read more
Founder & CEO
Gergely Toth
News
Feb 06, 2024
FinanzNachrichten
Cantabio: Cantabio Pharmaceuticals Inc.: Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a Novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson's Disease
Aug 17, 2023
BioSpace
Cantabio: Cantabio Pharmaceuticals Receives Additional Grant from The Michael J. Fox Foundation for Testing Its Novel Redox DJ-1 Protein-based ELISA Platform for the Diagnosis of Parkinson's Disease
Jan 05, 2022
FinanzNachrichten
Cantabio: Cantabio Pharmaceuticals Inc.: Cantabio Pharmaceuticals Awarded Grant From The Michael J. Fox Foundation to Develop Novel Small-Molecule Aggregation Inhibitors of the Tau Protein for the Treatment of Parkinson's Disease
Sep 16, 2020
Seeking Alpha
Cantabio: Cantabio secures grant to develop a protein-based biomarker for Parkinson's
Nov 13, 2019
FinanzNachrichten
Cantabio Pharmaceuticals: Cantabio Pharmaceuticals Inc.: Cantabio Announces Publication of Novel Study Demonstrating the Importance of the DJ-1 Protein in the Onset and Pathology of Alzheimer's and Parkinson's disease
Oct 21, 2019
FinanzNachrichten
Cantabio Pharmaceuticals: Cantabio Pharmaceuticals Inc.: Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate to Research the Therapeutic targeting of the DJ-1 Protein to Treat Immune Associated Diseases
Nov 08, 2018
BioPortfolio
Cantabio Pharmaceuticals: Cantabio Pharmaceuticals Inc CTBO Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23102018 Prices from USD $250
Oct 01, 2018
Benzinga
Cantabio Pharmaceuticals: Cantabio Pharmaceuticals to Present Latest Positive In Vivo Results From its DJ-1 Targeting Small Molecule Drug Development Program for Parkinson's Disease at the Milner Therapeutics Symposium at the University of Cambridge, UK
Aug 06, 2018
BioPortfolio
Cantabio Pharmaceuticals: Cantabio Pharmaceuticals Inc CTBO Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250
Jul 31, 2018
Benzinga
Cantabio Pharmaceuticals: Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Results in a Mice Model of Parkinson's disease of One of Its Orally Administered Novel DJ-1 Protein Targeting Therapeutic Candidates at the XXV International Symposium on Medicinal Chemistry in Ljubljana, Slovenia
Cantabio Competitors
1
2
3
4
5
6
7
8
9
10